GlassScriptPhysician profile
Shelby Brooks
NPI 1912561739
$3,756.82
in general payments reported to CMS, 2019-2025
25 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.25 · 2022: $177 · 2023: $1,054 · 2024: $1,099 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,169 · Education: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.26 |
| Education | $335.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $868.92 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $618.79 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $496.79 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $367.68 | 2023-2025 | Tezspire |
| Genzyme Corporation | $279.71 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $175.91 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $159.79 | 2023-2025 | |
| Optinose US, INC. | $91.84 | 2022-2024 | |
| Kaleo, INC. | $88.38 | 2023-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $82.27 | 2023-2025 | Orladeyo |
| Genentech USA, INC. | $69.11 | 2023-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $65.40 | 2021-2025 | Takhzyro, Eohilia |
| Ars Pharmaceuticals Operations, INC. | $54.45 | 2025 | Neffy |
| Integra Lifesciences Corporation | $52.64 | 2024-2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Greer Laboratories, INC. | $44.38 | 2023-2025 | Oralair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $42.85 | 2025 | |
| Neos Therapeutics, LP | $37.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.36 | 2023 | |
| Convatec INC. | $26.01 | 2024 | |
| Lilly USA, LLC | $19.96 | 2025 | Ebglyss |
| Cochlear Americas | $19.43 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Hologic Sales and Service, LLC | $16.83 | 2023 | Coolseal Generator |
| Medtronic, INC. | $15.65 | 2025 | Propel |
| Hikma Pharmaceuticals USA | $14.54 | 2023 | Ryaltris |
| Phathom Pharmaceuticals, INC. | $13.67 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelby Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.